| 000 | 01882 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516102404.0 | ||
| 264 | 0 | _c20121030 | |
| 008 | 201210s 0 0 eng d | ||
| 022 | _a1423-0232 | ||
| 024 | 7 |
_a10.1159/000339539 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNaraev, Boris G | |
| 245 | 0 | 0 |
_aCurrent status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. _h[electronic resource] |
| 260 |
_bOncology _c2012 |
||
| 300 |
_a117-27 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzenesulfonates _xtherapeutic use |
| 650 | 0 | 4 | _aCell Differentiation |
| 650 | 0 | 4 |
_aErbB Receptors _xmetabolism |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 |
_aHistone Deacetylases _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 | _aIndazoles |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aPyridines _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrroles _xpharmacology |
| 650 | 0 | 4 |
_aReceptors, Somatostatin _xmetabolism |
| 650 | 0 | 4 |
_aSirolimus _xanalogs & derivatives |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 |
_aSulfonamides _xtherapeutic use |
| 650 | 0 | 4 | _aSunitinib |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xmetabolism |
| 700 | 1 | _aStrosberg, Jonathan R | |
| 700 | 1 | _aHalfdanarson, Thorvardur R | |
| 773 | 0 |
_tOncology _gvol. 83 _gno. 3 _gp. 117-27 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000339539 _zAvailable from publisher's website |
| 999 |
_c21945615 _d21945615 |
||